<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448576</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-5010-TNBC-PCI</org_study_id>
    <nct_id>NCT02448576</nct_id>
  </id_info>
  <brief_title>PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy</brief_title>
  <official_title>A Phase III Randomized Controlled Trial of Prophylactic Cranial Irradiation in Patients With Advanced Triple Negative Breast Cancer Who Had a Response to First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>wang shusen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare whether prophylactic cranial irradiation in patients
      with advanced triple negative breast cancer who had a response to first line chemotherapy
      could prolong brain-metastasis free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, randomized, controlled, open, multicenter clinical trial, designed to
      assess the efficacy and safety of prophylactic cranial irradiation (PCI) in advanced triple
      negative breast cancer who response to the first line chemotherapy. Compare the PCI group
      with the observation group to evaluate brain metastasis-free survival,cumulative risk of
      brain metastases within 1 year,progression-free survival,overall survival,quality of life
      measured by the The Europe organization for research and treatment of cancer, Quality of life
      Questionnaire-cancer 30 (EORTC-QLQ-C30) questionnaire score and function of central nervous
      measured by the The Europe organization for research and treatment of cancer, Quality of life
      Questionnaire-brain cancer 20 (EORTC-QLQ-BN20) questionnaire score in women with advanced
      triple negative breast cancer who response to the first line chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brain metastasis-free survival</measure>
    <time_frame>eight years</time_frame>
    <description>time from randomization to brain metastasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative risk of brain metastases within 1 year</measure>
    <time_frame>one year</time_frame>
    <description>the percent of subjects occurring brain metastases with 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>eight years</time_frame>
    <description>time from randomization to disease progression or death(upon which happen earlier)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>eight years</time_frame>
    <description>time from randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality score</measure>
    <time_frame>eight years</time_frame>
    <description>quality of life measured by the EORTC-QLQ-C30 questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central nervous function score</measure>
    <time_frame>eight years</time_frame>
    <description>function of central nervous measured by the EORTC-QLQ-BN20 questionnaire score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Brain Metastasis</condition>
  <arm_group>
    <arm_group_label>PCI group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving prophylactic cranial irradiation after response to first line chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>prophylactic cranial irradiation</intervention_name>
    <description>Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy</description>
    <arm_group_label>PCI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent;

          2. Age of 18 to 65 years;

          3. Documented advanced breast cancer, clinical and pathological confirmed;

          4. Immunohistochemical examination:ER&lt;1%+, progestin receptor (PR)&lt;1%+, HER-2 -/+ or
             HER-2(++)with negative result of FISH;

          5. A response after four to eight cycles of first line chemotherapy;

          6. Life expectancy longer than six months evaluated by investigator;

          7. A performance status of 0 to 2, according to the criteria of the World Health
             Organization (with a higher score indicating a poorer performance status)

          8. Less than grade 1( Common Terminology Criteria grade version 4.0) of treatment-related
             toxicities;

          9. Adequate baseline organ function.

        Exclusion Criteria:

          1. History of another malignancy.

          2. Pregnancy or gestation

          3. Definite diagnosed of central nervous system (CNS)or leptomeningeal metastases

          4. Serious cardiac illness or medical condition

          5. Known history of related central nervous system or leptomeningeal disease

          6. Cognition impairment or suffering from mental illness

          7. Demand a long-term oral administration of psychotropic drugs

          8. Have a concurrent disease or condition that may interfere with study participation, or
             any serious medical disorder that would interfere with the subject's safety (for
             example, active or uncontrolled infection, currently active/requiring anti-viral
             therapy hepatic or biliary disease)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shusen Wang</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>fei Xu</last_name>
    <phone>862087342693</phone>
    <email>xufei@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>fei xu, M.D.</last_name>
      <phone>862087342693</phone>
      <email>xufei@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer. 2012 Jan 31;106(3):440-6. doi: 10.1038/bjc.2011.597. Epub 2012 Jan 10.</citation>
    <PMID>22233926</PMID>
  </reference>
  <reference>
    <citation>Saip P, Cicin I, Eralp Y, Karagol H, Kucucuk S, Cosar Alas R, Yavuz E, Dincer M, Saglam E, Topuz E. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis. J Neurooncol. 2009 Jun;93(2):243-51. doi: 10.1007/s11060-008-9769-0. Epub 2008 Dec 20.</citation>
    <PMID>19099196</PMID>
  </reference>
  <reference>
    <citation>Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P, Gachet J, Labib A, Mouret-Fourme E. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer. 2011 Sep 19;11:395. doi: 10.1186/1471-2407-11-395.</citation>
    <PMID>21929800</PMID>
  </reference>
  <reference>
    <citation>Huang F, Alrefae M, Langleben A, Roberge D. Prophylactic cranial irradiation in advanced breast cancer: a case for caution. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):752-8. doi: 10.1016/j.ijrobp.2008.05.031. Epub 2008 Oct 26.</citation>
    <PMID>18954943</PMID>
  </reference>
  <reference>
    <citation>Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983 Dec 15;52(12):2349-54.</citation>
    <PMID>6640506</PMID>
  </reference>
  <reference>
    <citation>Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007 Aug 16;357(7):664-72.</citation>
    <PMID>17699816</PMID>
  </reference>
  <reference>
    <citation>Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 Aug 12;341(7):476-84.</citation>
    <PMID>10441603</PMID>
  </reference>
  <reference>
    <citation>Ahn HK, Park YH, Lee SJ, Park S, Maeng CH, Park W, Choi DH, Hur SJ, Ahn JS, Im YH. Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. Springerplus. 2013 Mar 28;2(1):136. doi: 10.1186/2193-1801-2-136. Print 2013 Dec.</citation>
    <PMID>23667803</PMID>
  </reference>
  <reference>
    <citation>Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004 Sep 1;22(17):3608-17. Review.</citation>
    <PMID>15337811</PMID>
  </reference>
  <reference>
    <citation>Bai B, Yuan ZY, Liu DG, Teng XY, Wang SS. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases. Chin J Cancer. 2010 Apr;29(4):413-9.</citation>
    <PMID>20346218</PMID>
  </reference>
  <reference>
    <citation>Paterson AH, Agarwal M, Lees A, Hanson J, Szafran O. Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer. 1982 Feb 15;49(4):651-4.</citation>
    <PMID>7055779</PMID>
  </reference>
  <reference>
    <citation>Carey LA, Ewend MG, Metzger R, Sawyer L, Dees EC, Sartor CI, Moore DT, Graham ML. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat. 2004 Dec;88(3):273-80.</citation>
    <PMID>15609130</PMID>
  </reference>
  <reference>
    <citation>Al-Shamy G, Sawaya R. Management of brain metastases: the indispensable role of surgery. J Neurooncol. 2009 May;92(3):275-82. doi: 10.1007/s11060-009-9839-y. Epub 2009 Apr 9. Review.</citation>
    <PMID>19357955</PMID>
  </reference>
  <reference>
    <citation>Fokstuen T, Wilking N, Rutqvist LE, Wolke J, Liedberg A, Signomklao T, Fernberg JO. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat. 2000 Aug;62(3):211-6.</citation>
    <PMID>11072785</PMID>
  </reference>
  <reference>
    <citation>Santarelli JG, Sarkissian V, Hou LC, Veeravagu A, Tse V. Molecular events of brain metastasis. Neurosurg Focus. 2007 Mar 15;22(3):E1. Review.</citation>
    <PMID>17608351</PMID>
  </reference>
  <reference>
    <citation>Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006 Dec 20;24(36):5658-63. Epub 2006 Nov 13.</citation>
    <PMID>17102066</PMID>
  </reference>
  <reference>
    <citation>Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006 Aug 15;107(4):696-704.</citation>
    <PMID>16826579</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>wang shusen</investigator_full_name>
    <investigator_title>Shusen Wang, M.D. Department of Medical Oncology, Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>phase 3 randomized controlled trial</keyword>
  <keyword>prophylactic cranial irradiation</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>brain metastasis</keyword>
  <keyword>advanced breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

